Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug;23(8):1182-6.
doi: 10.1007/s11606-008-0636-7. Epub 2008 May 1.

Prevalence of musculoskeletal pain and statin use

Catherine Buettner  1 , Roger B Davis, Suzanne G Leveille, Murray A Mittleman, Kenneth J Mukamal
Affiliations

Prevalence of musculoskeletal pain and statin use

Catherine Buettner et al. J Gen Intern Med. 2008 Aug.

Abstract

Background: Muscle effects are the most common reported adverse effects of 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins). However, in placebo-controlled trials the incidence of muscle pain is most often similar for placebo and active control groups.

Objective: We sought to evaluate whether statin use was associated with a higher prevalence of musculoskeletal pain in a nationally representative sample.

Methods: Cross-sectional analysis using data from the National Health and Nutrition Examination Survey (NHANES) 1999-2002. Participants were 3,580 adults > or =40 years without arthritis who were interviewed at home and examined in a mobile examination center. Participants were asked about sociodemographic characteristics, health conditions, medication use, and musculoskeletal pain. Height, weight, blood pressure, ankle brachial index, and cholesterol were measured.

Measurements and main results: Prevalence and adjusted odds ratios (OR) of any musculoskeletal pain and musculoskeletal pain in 4 different anatomical regions (neck/upper back, upper extremities, lower back, and lower extremities) by statin use during the last 30 days. Among statin users (n = 402), 22.0% (95%CI 18.0-26.7%) reported musculoskeletal pain in at least 1 anatomical region during the last 30 days, compared with 16.7% (95%CI 15.1-18.4%) of those who did not use a statin. Compared to persons who did not use statins, those who used statins had multivariable-adjusted odds ratios (95%CI; p value) of 1.50 (1.07-2.11; p = .01) for any musculoskeletal pain, 1.59 (1.04-2.44, p = .03) for lower back pain, and 1.50 (1.02-2.22, p = .03) for lower extremity pain.

Conclusion: Musculoskeletal pain is common in adults > or =40 years without arthritis. In this nationally representative sample, statin users were significantly more likely to report musculoskeletal pain.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Unadjusted weighted prevalence estimates (percent) and 95% confidence intervals of any musculoskeletal pain and musculoskeletal pain at 4 different anatomical regions according to statin use (p = .01, p = .86, p = .80, p = .26, p = .03, respectively).
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1001/jama.290.17.2243', 'is_inner': False, 'url': 'https://doi.org/10.1001/jama.290.17.2243'}, {'type': 'PubMed', 'value': '14600168', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14600168/'}]}
    2. Mitka M. Expanding statin use to help more at-risk patients is causing financial heartburn. JAMA. 2003;290(17):2243–5. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.jacc.2006.04.070', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.jacc.2006.04.070'}, {'type': 'PubMed', 'value': '16875966', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16875966/'}]}
    2. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438–45. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0002-9149(03)00506-X', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0002-9149(03)00506-x'}, {'type': 'PubMed', 'value': '12867252', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12867252/'}]}
    2. Fonarow GC, Watson KE. Effective strategies for long-term statin use. Am J Cardiol. 2003;92(1A):27i–34i. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s11883-002-0060-0', 'is_inner': False, 'url': 'https://doi.org/10.1007/s11883-002-0060-0'}, {'type': 'PubMed', 'value': '11772420', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11772420/'}]}
    2. Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep. 2002;4(1):34–41. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0002-9343(02)01428-6', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0002-9343(02)01428-6'}, {'type': 'PubMed', 'value': '12505120', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12505120/'}]}
    2. Sacks FM. Adherence to statin therapy: why aren’t we doing better? Am J Med. 2002;113(8):685–6. - PubMed

Substances

LinkOut - more resources